Filter by: patients
Home > Community Treatment Reports and Side Effects > ALS Phase 3 Study Ceftriaxone Treatment Report
What is ALS Phase 3 Study Ceftriaxone?

NCT00349622 is a clinical trial with ceftriaxone in subjects with amyotrophic lateral sclerosis (ALS). Other study IDs include: U01NS049640-02, NINDS, U01NS049640-02, NINDS CRC.

Reported Purpose & Efficacy

Reasons and Efficacy
Purpose # of patients
# of patients with evaluations Efficacy
Major
Moderate
Slight
None
Can’t tell
ALS (Amyotrophic Lateral Sclerosis) 12 10 Efficacy_slight Efficacy_none Efficacy_cant_tell
Participate in clinical trial 9 5 Efficacy_cant_tell

See all 18 patients currently using ALS Phase 3 Study Ceftriaxone

Mouse over the table for more information

Reported Side Effects

Side effects as an overall problem

Severe
 1
Moderate
 5
Mild
 4
None
 4

Commonly reported side effects, conditions, and hospitalizations associated with ALS Phase 3 Study Ceftriaxone

Gallstones 3
Yeast Infection (candida) 2
Beginning of gallstones 2
Oral thrush (candidiasis) 1
Fever 1
Loose stools 1
See all 16 reported side effects ▼ See top 6 reported side effects ▲

Reported Schedules

  1 other daily 2 mg daily 2 g daily 2 other daily 4 g daily 30 mg daily 40 mg daily 50 mg daily
  1 Number of Patients: 1 2 Number of Patients: 2 1 Number of Patients: 1 2 Number of Patients: 2 9 Number of Patients: 9 1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1  

Reported Stop Reasons

Why Patients Stopped Using ALS Phase 3 Study Ceftriaxone (multiple reasons could be selected)
Reason # Patients Percentage of patients
Side effects too severe 2   Side effects too severe: 50%
Did not seem to work 1   Did not seem to work: 25%
Other 1   Other: 25%

See all 4 patients who’ve stopped using ALS Phase 3 Study Ceftriaxone

Reported Duration See details about how long patients take this treatment ▼

Currently Using ALS Phase 3 Study Ceftriaxone

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0

Stopped Using ALS Phase 3 Study Ceftriaxone

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0

Reported Adherence, Burden & Cost See details from patient evaluations ▼

Adherence

Taking treatment as prescribed

Adherence of ALS Phase 3 Study Ceftriaxone

Always
 12 86%
Usually
 1 7%
Sometimes
 0 0%
Never
 1 7%

Burden

Difficulty being on treatment

Burden of ALS Phase 3 Study Ceftriaxone

Very
 3 21%
Somewhat
 5 36%
A little
 5 36%
Not at all
 1 7%

Cost

Paid out of pocket

Cost of ALS Phase 3 Study Ceftriaxone

$200+
 1 8%
$100-199
 0 0%
$50-99
 0 0%
$25-49
 0 0%
< $25
 11 92%

Report created on May 23, 2012.